Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2025-05-21 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
国新证券股份有限公司关于云南生物谷药业股份有限公司2024年度持续督导跟踪报告
Regulatory Filings
2025-05-21 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a 2024 annual shareholders meeting resolution announcement for Yunnan Shengwu Gu Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results on various proposals including the 2024 annual report and financial decisions, and legal opinions confirming the meeting's legality. The content is focused on the resolutions passed at the Annual General Meeting (AGM), including voting outcomes and procedural compliance. It does not contain the full annual report or financial statements themselves, but rather the official announcement of the AGM decisions and voting results. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and is a formal announcement of meeting resolutions and voting results, not the report itself or a presentation.
2025-05-21 Chinese
公司章程
Governance Information Classification · 100% confidence The document is titled as the "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and governance rules. It references Chinese company law and securities regulations, and extensively covers governance and operational rules of the company. There is no indication that this is an annual report, financial statement, earnings release, or any other financial or regulatory filing. Instead, it is a governance document outlining the internal rules and structure of the company. Therefore, the document best fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance provisions, not just an announcement or summary, so it is not an RPA or RNS.
2025-05-21 Chinese
上海邦信阳律师事务所关于云南生物谷药业股份有限公司2024年年度股东会之法律意见书
Regulatory Filings
2025-05-21 Chinese
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It details a performance explanation meeting (业绩说明会) held on May 15, 2025, discussing the 2024 annual report and 2025 business plans. The content includes Q&A with investors about company operations, product pipeline, market challenges, and strategic plans. The document is relatively short (2243 characters) and focuses on the investor relations event rather than presenting full financial statements or detailed financial data. It is not the annual report itself but a record of an earnings explanation meeting. This fits best with the category of an Investor Presentation (IP), which covers detailed presentations for investors focusing on financials, strategy, and market position. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements. It is not a Call Transcript (CT) since it is a written record of a scheduled investor meeting rather than a conference call transcript. Therefore, the most appropriate classification is Investor Presentation (IP).
2025-05-18 Chinese
关于变更持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representatives for the company. It details personnel changes in the sponsor representatives and includes a brief biography of the new representative. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other report types. This fits the category of Board/Management Information (MANG) as it concerns changes in key company representatives related to regulatory supervision roles.
2025-05-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.